Ország: Európai Unió
Nyelv: angol
Forrás: EMA (European Medicines Agency)
pantoprazole
Takeda GmbH
A02BC02
pantoprazole
Proton pump inhibitors
Gastroesophageal Reflux
Short-term treatment of reflux symptoms (e.g. heartburn, acid regurgitation) in adults.
Revision: 18
Withdrawn
2009-06-11
21 B. PACKAGE LEAFLET Medicinal product no longer authorised 22 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT PANTOLOC CONTROL 20 MG GASTRO-RESISTANT TABLETS pantoprazole READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Always take this medicine exactly as described in this leaflet or as your doctor or pharmacist have told you. - Keep this leaflet. You may need to read it again. - Ask your pharmacist if you need more information or advice. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. - You must talk to a doctor if you do not feel better or if you feel worse after 2 weeks. - You should not take PANTOLOC Control tablets for more than 4 weeks without consulting a doctor. WHAT IS IN THIS LEAFLET 1. What PANTOLOC Control is and what it is used for 2. What you need to know before you take PANTOLOC Control 3. How to take PANTOLOC Control 4. Possible side effects 5. How to store PANTOLOC Control 6. Contents of the pack and other information 1. WHAT PANTOLOC CONTROL IS AND WHAT IT IS USED FOR PANTOLOC Control contains the active substance pantoprazole, which blocks the ‘pump’ that produces stomach acid. Hence it reduces the amount of acid in your stomach. PANTOLOC Control is used for the short-term treatment of reflux symptoms (for example heartburn, acid regurgitation) in adults. Reflux is the backflow of acid from the stomach into the gullet (“foodpipe”), which may become inflamed and painful. This may cause you symptoms such as a painful burning sensation in the chest rising up to the throat (heartburn) and a sour taste in the mouth (acid regurgitation). You may experience relief from your acid reflux and heartburn symptoms after just one day of treatment with PANTOLOC Control, but this medicine is not meant to bring immediate relief. It may be necessary to take the tablets for 2-3 consecutive days to relieve the symptoms. You must talk Olvassa el a teljes dokumentumot
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS Medicinal product no longer authorised 2 1. NAME OF THE MEDICINAL PRODUCT PANTOLOC Control 20 mg gastro-resistant tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each gastro-resistant tablet contains 20 mg pantoprazole (as sodium sesquihydrate). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Gastro-resistant tablet. Yellow, oval, biconvex film-coated tablets imprinted with “P20” in brown ink on one side. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS PANTOLOC Control is indicated for short-term treatment of reflux symptoms (e.g. heartburn, acid regurgitation) in adults. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology The recommended dose is 20 mg pantoprazole (one tablet) per day. It might be necessary to take the tablets for 2-3 consecutive days to achieve improvement of symptoms. Once complete relief of symptoms has occurred, treatment should be discontinued. The treatment should not exceed 4 weeks without consulting a doctor. If no symptom relief is obtained within 2 weeks of continuous treatment, the patient should be instructed to consult a doctor. Special populations No dose adjustment is necessary in elderly patients or in those with impaired renal or liver function. _ _ _Paediatric population _ PANTOLOC Control is not recommended for use in children and adolescents below 18 years of age due to insufficient data on safety and efficacy. Method of administration PANTOLOC Control 20 mg gastro-resistant tablets should not be chewed or crushed, and should be swallowed whole with liquid before a meal. Medicinal product no longer authorised 3 4.3 CONTRAINDICATIONS Hypersensitivity to the active substance, or to any of the excipients listed in section 6.1. Co-administration of pantoprazole is not recommended with HIV protease inhibitors for which absorption is dependent on acidic intragastric pH such as atazanavir, nelfinavir; due to significant reduction in their bioavailability (see section 4.5). 4.4 SPECIAL WARNINGS AND PRECA Olvassa el a teljes dokumentumot